CA2925057A1 - Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer - Google Patents
Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer Download PDFInfo
- Publication number
- CA2925057A1 CA2925057A1 CA2925057A CA2925057A CA2925057A1 CA 2925057 A1 CA2925057 A1 CA 2925057A1 CA 2925057 A CA2925057 A CA 2925057A CA 2925057 A CA2925057 A CA 2925057A CA 2925057 A1 CA2925057 A1 CA 2925057A1
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- beta
- inhibitor
- her2
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361885302P | 2013-10-01 | 2013-10-01 | |
| US61/885,302 | 2013-10-01 | ||
| PCT/EP2014/071028 WO2015049280A1 (en) | 2013-10-01 | 2014-10-01 | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2925057A1 true CA2925057A1 (en) | 2015-04-09 |
Family
ID=51655742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2925057A Abandoned CA2925057A1 (en) | 2013-10-01 | 2014-10-01 | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20160319032A1 (enExample) |
| EP (1) | EP3052523B1 (enExample) |
| JP (2) | JP6527508B2 (enExample) |
| CN (1) | CN106232625B (enExample) |
| AU (1) | AU2014331118B2 (enExample) |
| CA (1) | CA2925057A1 (enExample) |
| WO (1) | WO2015049280A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| EP3386529A2 (en) * | 2015-12-11 | 2018-10-17 | Ruprecht-Karls-Universität Heidelberg | Combined preparations of pkm2 modulators and hmgb1 |
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| EA201892716A1 (ru) * | 2016-06-14 | 2019-05-31 | Мерк Шарп И Доум Корп. | Антитела к фактору свертывания xi |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN106950371B (zh) * | 2017-02-17 | 2019-03-08 | 张灏 | Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途 |
| US20200109205A1 (en) * | 2017-03-31 | 2020-04-09 | The Regents Of The University Of California | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| US12624086B2 (en) | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| AU2020224164A1 (en) * | 2019-02-22 | 2022-02-10 | Candel Therapeutics, Inc. | GMCI and DDRI combination therapy for treating cancer |
| TWI884192B (zh) | 2019-12-05 | 2025-05-21 | 美商西健公司 | 抗αＶβ６抗體及抗體-藥物結合物 |
| US11579085B2 (en) * | 2020-07-17 | 2023-02-14 | Robert Bosch Gmbh | Sensing devices |
| CN114195893A (zh) * | 2020-09-17 | 2022-03-18 | 百奥泰生物制药股份有限公司 | 抗整联蛋白抗体或抗原结合片段及其应用 |
| CN118440187A (zh) * | 2023-01-05 | 2024-08-06 | 郴州市第一人民医院 | 一种抗SARS-like冠状病毒和/或新冠突变株的广谱抗体及其应用 |
| CN117603348B (zh) * | 2023-11-24 | 2024-08-09 | 优睿赛思(武汉)生物科技有限公司 | 抗新型冠状病毒s蛋白的全人源化抗体及其应用 |
| EP4595981A1 (en) * | 2024-02-01 | 2025-08-06 | Jack Elands | Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody |
| WO2025163120A1 (en) | 2024-02-01 | 2025-08-07 | Adcytherix Sas | ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY147019A (en) * | 2002-03-13 | 2012-10-15 | Biogen Idec Inc | Anti-alpha v beta 6 antibodies |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| WO2008112004A2 (en) * | 2006-08-03 | 2008-09-18 | Astrazeneca Ab | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF |
| CN105017420B (zh) * | 2012-02-17 | 2019-05-28 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
-
2014
- 2014-10-01 CN CN201480065738.4A patent/CN106232625B/zh active Active
- 2014-10-01 CA CA2925057A patent/CA2925057A1/en not_active Abandoned
- 2014-10-01 AU AU2014331118A patent/AU2014331118B2/en active Active
- 2014-10-01 EP EP14777632.2A patent/EP3052523B1/en not_active Not-in-force
- 2014-10-01 US US15/026,350 patent/US20160319032A1/en not_active Abandoned
- 2014-10-01 WO PCT/EP2014/071028 patent/WO2015049280A1/en not_active Ceased
- 2014-10-01 JP JP2016519326A patent/JP6527508B2/ja active Active
-
2018
- 2018-11-06 US US16/181,907 patent/US20190389967A1/en not_active Abandoned
-
2019
- 2019-03-20 JP JP2019052035A patent/JP2019142876A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190389967A1 (en) | 2019-12-26 |
| CN106232625B (zh) | 2020-04-24 |
| JP6527508B2 (ja) | 2019-06-05 |
| CN106232625A (zh) | 2016-12-14 |
| AU2014331118A1 (en) | 2016-05-19 |
| EP3052523B1 (en) | 2021-03-10 |
| US20160319032A1 (en) | 2016-11-03 |
| EP3052523A1 (en) | 2016-08-10 |
| HK1232235A1 (zh) | 2018-01-05 |
| AU2014331118B2 (en) | 2019-07-25 |
| WO2015049280A1 (en) | 2015-04-09 |
| JP2016539083A (ja) | 2016-12-15 |
| JP2019142876A (ja) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014331118B2 (en) | Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer | |
| CA2658612C (en) | Antibodies directed to .alpha.v.beta.6 and uses thereof | |
| US8119130B2 (en) | Targeted binding agents directed to KDR and uses thereof—035 | |
| US8026344B2 (en) | Targeted binding agents directed to uPAR and uses thereof | |
| US20120107324A1 (en) | TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF | |
| JP2012502649A (ja) | Ｃｄ１０５を対象とする標的結合剤およびその使用 | |
| WO2010072740A2 (en) | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF | |
| WO2010072741A9 (en) | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR | |
| HK1232235B (en) | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190814 |
|
| FZDE | Discontinued |
Effective date: 20220509 |